Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants
Source: View publication →
A single intramuscular dose of the long-acting monoclonal antibody nirsevimab significantly reduced the incidence of medically attended lower respiratory tract infections caused by respiratory syncytial virus in healthy term and late-preterm infants.
Key Findings
Study Design
Study Limitations
Clinical Significance
Nirsevimab represents a paradigm shift in RSV prevention, offering a simple, single-dose monoclonal antibody option for the general infant population, potentially replacing or augmenting existing high-risk-only prophylaxis regimens like palivizumab.
Historical Context
For decades, RSV prevention was limited to high-risk infants via monthly injections of palivizumab. The development of nirsevimab, an extended half-life monoclonal antibody targeting the prefusion F protein, addresses the long-standing need for a practical, season-long preventative measure for all infants.
Guided Discussion
High-yield insights from every perspective
Explain the pharmacological mechanism that allows nirsevimab to be administered as a single dose for the entire RSV season, whereas palivizumab requires monthly injections.
Key Response
Nirsevimab is a monoclonal antibody targeting the prefusion conformation of the RSV fusion (F) protein. It features a triple amino acid substitution (YTE) in the Fc region, which increases its affinity for the neonatal Fc receptor (FcRn). This enhancement promotes the recycling of the antibody back into the circulation rather than degradation, extending its half-life to approximately 60 to 70 days, which is significantly longer than the 20-day half-life of palivizumab.
In a healthy term infant presenting during their first RSV season, how do the results of the MELODY trial regarding 'medically attended lower respiratory tract infection' (MALRTI) influence your counseling on the benefits of nirsevimab compared to supportive care alone?
Key Response
The MELODY trial showed that nirsevimab reduced the incidence of RSV-associated MALRTI by 74.5% compared to placebo. Residents should be able to explain to parents that while most RSV is mild, this intervention significantly lowers the risk of the child needing a clinic or emergency room visit, effectively shifting the burden of disease away from the outpatient and acute care settings during peak season.
The MELODY trial utilized a primary endpoint of medically attended LRTI. Discuss the clinical and immunological implications of 'breakthrough' infections observed in the nirsevimab group—specifically, do these represent a failure of neutralization or an expected decay in antibody titers over the 150-day observation period?
Key Response
Fellows must integrate pharmacokinetic data with clinical outcomes. Breakthroughs may occur if the viral inoculum overcomes the passive antibody concentration or if mutations occur at the highly conserved site Ø on the F protein. Analysis of the trial data suggests that protection remains high throughout the 150-day period, suggesting that most breakthroughs are likely due to host factors or high-exposure events rather than a rapid loss of therapeutic levels.
The MELODY trial demonstrates efficacy in healthy infants, who represent the largest absolute number of RSV hospitalizations. How does this shift the traditional 'high-risk' prophylaxis paradigm, and what are the teaching points for trainees regarding the difference between passive immunization and active vaccination?
Key Response
Historically, RSV prophylaxis was restricted to high-risk groups (preterm, CHD, CLD) due to the costs of palivizumab. Nirsevimab moves the strategy toward universal prevention. Attendings should teach that nirsevimab provides immediate 'passive' immunity (pre-formed antibodies), which is distinct from 'active' vaccination (inducing the infant's own immune response), making it an ideal strategy for neonates with immature immune systems entering their first viral season.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Critique the statistical handling of the 'primary pool' analysis in the MELODY trial, which was necessitated by the COVID-19 pandemic. How might the disruption of normal RSV seasonality during the study period affect the generalizability of the reported efficacy and the calculation of the absolute risk reduction?
Key Response
The pandemic led to a period of near-zero RSV circulation, causing a hiatus in enrollment. The researchers analyzed a 'primary pool' of infants enrolled before the hiatus. A PhD researcher would note that if RSV seasons post-pandemic are more or less severe, the Absolute Risk Reduction (ARR) and Number Needed to Treat (NNT) observed in the trial may fluctuate, even if the Relative Risk Reduction (RRR) remains stable, impacting future cost-effectiveness models.
As a reviewer, evaluate the potential for 'diagnostic overshadowing' or bias in the MELODY trial's secondary endpoint of hospitalization. Since the study was double-blinded, could the reduction in medically attended visits have indirectly influenced the rate of hospitalization by altering the threshold for physician referral?
Key Response
Editors look for subtle biases. If a clinician knows an infant is part of an RSV prevention trial, they might monitor them more closely or differently. However, because the trial was robustly double-blinded, the reduction in hospitalizations (62.1% in the primary pool) likely reflects a true reduction in disease severity. A tough reviewer would scrutinize whether the criteria for 'hospitalization' were standardized across international study sites to ensure the endpoint's validity.
How does the evidence from the MELODY trial support a change in the AAP Red Book recommendations from a targeted approach (palivizumab for <29 weeks GA) to a universal approach (nirsevimab for all infants)? What specific evidence gaps remain regarding long-term safety?
Key Response
The MELODY trial provided high-quality (Level 1) evidence for healthy infants ≥35 weeks GA. Combined with the MEDLEY trial (comparing nirsevimab to palivizumab in high-risk infants), the data supports the ACIP/AAP recommendation for a single dose for all infants <8 months. The committee must consider that while efficacy is clear, ongoing surveillance is required to monitor for rare adverse events and the potential emergence of RSV variants that could escape neutralization.
Clinical Landscape
Noteworthy Related Trials
IMpact-RSV Trial
Tested
Palivizumab
Population
Preterm infants and children with chronic lung disease
Comparator
Placebo
Endpoint
RSV-related hospitalization
MEDLEY Trial
Tested
Nirsevimab
Population
Preterm infants and infants with chronic lung disease or hemodynamically significant congenital heart disease
Comparator
Palivizumab
Endpoint
Safety and serum concentration of nirsevimab
PROTECT Trial
Tested
Nirsevimab
Population
Healthy preterm and term infants
Comparator
Placebo
Endpoint
Medically attended RSV-associated lower respiratory tract infection
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis